Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy

Antiviral Therapy

Volumn 14, Issue 1, 2009, Pages 45-54

  Hsu, Ching Sheng ^a,b   Liu, Chen Hua ^b   Liu, Chun Jen ^b   Chen, Chi Ling ^b   Lai, Ming Yang ^b   Chen, Pei Jer ^b   Chen, Ding Shinn ^b   Kao, Jia Horng ^b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS LOAD;

EID: 84984585908     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.1177/135965350901400101     Document Type: Article

References (40)

1. Kao JH, Chen DS. Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol 2000; 15 Suppl:E91-E96.
2. Chen DS. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp 1995; 25:27-32.
3. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
4. Fried MW Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36:S237-S244.
5. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26:122S-127S.
6. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997; 113:558-566.
7. Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997; 113:1647-1653.
8. Zeuzem S, Lee JH, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27:1149-1156.
9. Shire NJ, Horn PS, Rouster SD, Stanford S, Eyster ME, Sherman KE. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/ HIV-1-coinfected patients with hemophilia. Hepatology 2006; 44:1146-1157.
10. Chayama K, Tsubota A, Kobayashi M, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25:745-749.
11. Ebeling E Lappalainen M, Vuoristo M, et al. Factors predicting interferon treatment response in patients with chronic hepatitis C: late viral clearance does not preclude a sustained response. Am J Gastroenterol 2001; 96:1237-1242.
12. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37:600-609.
13. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of U.S. veterans to treatment for the hepatitis C virus. Hepatology 2007; 46:37-47.
14. Missiha S, Heathcote J, Arenovich T, Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102:2181-2188.
15. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38:639-644.
16. Akuta N, Suzuki E Suzuki Y, et al. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol 2005; 75:550-558.
17. Persico M, Capasso M, Persico E, et al. Suppressor of cyrokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 2007; 46:1009-1015.
18. Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepat 2003; 10:16-22.
19. Lin R, Liddle C, Byth K, Farrell GC. Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepat 1996; 3:85-96.
20. National Institutes of Health (US). National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 5 Suppl 1:S3-S20.
21. Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35:930-936.
22. Layden-Almer JE, Ribeiro RM Wiley T, Perelson AS, Layden TJ. Vital dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37:1343-1350.
23. Ballesteros AL, Franco S, Fuster D, et al. Early HCV dynamics on peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS 2004; 18:59-66.
24. Hsu CS, Liu CJ, Lai MY, Chen PJ, Kao JH, Chen DS. Early viral kinetics during treatment chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology 2007; 50:310-315.
25. Yeh SH Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004; 41:659-666.
26. Kao JH Lin HH, Chen PJ, et al. Serotyping of hepatitis C virus chronic type C hepatitis in Taiwan: correlation with genotypes. J Gastroenterol 1996; 31:224-227.
27. Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35:201-207.
28. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
29. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2167-2474.
30. Lee SD, Yu ML, Cheng PN, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese Natients with chronic hepatitis C in Taiwan. J Viral Hepat 2005; 12:283-291.
31. Kerniner N, Neff GW. Managing chronic hepatitis C in the difficult-to-treat patient. Liver Int 2007; 27:1297-1310.
32. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107.
33. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96:12766-12771.
34. Andre P, Komurian-Pradel F, Deforges S, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76:6919-6928.
35. Ludewig B, Jaggi M, Dumrese T, et al. Hypercholesterolemia exacerbates virus-induced immunopathologic liver disease via suppression of antiviral cytotoxic T cell responses. J Immunol 2001; 166:3369-3376.
36. Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a market for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006; 107:2212-2222.
37. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-410.
38. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008; 46:78-84.
39. Akuta N, Suzuki E, Kawamura Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007; 79:1686-1695.
40. Yu ML, Dai CY, Huang JE et al. A randornised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56:5S3-5S9.